Drug Trial Radar · NCT02333331
Dose Range Finding Study of Bimagrumab in Sarcopenia
Last checked: Nov 19, 2026Latest source record: Jan 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
217
Actual
Start
Dec 9, 2014
Primary completion
Jun 26, 2018
Study completion Jun 28, 2018
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 7, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to determine the efficacy of repeat dosing with multiple dose levels of bimagrumab on patient physical function, skeletal muscle mass and strength in older adults with sarcopenia. In addition, this study generated data on the safety, tolerability, and pharmacokinetics of bimagrumab in older adults with sarcopenia.
Conditions
- Sarcopenia
Interventions
bimagrumabDrug
Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.
placeboOther
Placebo will be administered as an intravenous infusion starting on Day 1 until week 21.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Total Short Physical Performance Battery (SPPB) Score to Week 25Time frame: Baseline, week 25
Locations
58 sites in 13 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Little Rock, Arkansas
Novartis Investigative Site
Cypress, California
Novartis Investigative Site
La Jolla, California
Novartis Investigative Site
Farmington, Connecticut
Novartis Investigative Site
Gainesville, Florida
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Miami Lakes, Florida
Novartis Investigative Site
Orlando, Florida
Novartis Investigative Site
Gainesville, Georgia
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Rochester, Minnesota
Novartis Investigative Site
High Point, North Carolina
Novartis Investigative Site
Columbus, Ohio
Novartis Investigative Site
Spartanburg, South Carolina
Novartis Investigative Site
Mesquite, Texas
Novartis Investigative Site
San Antonio, Texas
Novartis Investigative Site
Madison, Wisconsin
Novartis Investigative Site
Adelaide, South Australia, Australia
Novartis Investigative Site
St Albans, Victoria, Australia
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Brno, Czechia
Novartis Investigative Site
Opava, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Copenhagen, Denmark
Novartis Investigative Site
Copenhagen NV, Denmark
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Pessac, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Würzburg, Germany
Novartis Investigative Site
Ōbu, Aichi-ken, Japan
Novartis Investigative Site
Toyohashi, Aichi-ken, Japan
Novartis Investigative Site
Mizunami, Gifu, Japan
Novartis Investigative Site
Nara, Nara, Japan
Novartis Investigative Site
Kawachi-Nagano, Osaka, Japan
Novartis Investigative Site
Kitaadachigun Inamachi, Saitama, Japan
Novartis Investigative Site
Kitamoto, Saitama, Japan
Novartis Investigative Site
Yoshinogawa, Tokushima, Japan
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.